Summary
HCA Healthcare, Inc. filed an 8-K on September 12, 2018, announcing a significant leadership transition. R. Milton Johnson will retire as Chief Executive Officer (CEO) effective December 31, 2018, but will remain as Chairman of the Board until the 2019 annual meeting and continue as an Executive Advisor through December 31, 2019. This move is accompanied by the appointment of Samuel N. Hazen as the new CEO, effective January 1, 2019. Mr. Hazen, who has a long tenure with HCA, including serving as President and COO, will also join the Board of Directors. Investors should note the planned succession, which appears to be an internal promotion, suggesting a degree of continuity in leadership strategy. The filing also details the terms of R. Milton Johnson's amended employment agreement, outlining his compensation and benefits during his transition period and advisory role. This transition marks a new chapter for HCA's executive leadership, with Mr. Hazen set to guide the company forward.
Key Highlights
- 1R. Milton Johnson to retire as CEO on December 31, 2018, transitioning to Chairman until the 2019 annual meeting.
- 2Samuel N. Hazen appointed as the new CEO, effective January 1, 2019.
- 3Samuel N. Hazen will also join the HCA Board of Directors.
- 4Mr. Johnson will remain employed as an Executive Advisor through December 31, 2019.
- 5Details provided on Mr. Johnson's amended employment agreement, including base salary, bonus eligibility, and restricted stock units (RSUs) for his transition and advisory roles.
- 6The succession plan indicates an internal promotion for the CEO role, promoting continuity.
- 7The Board size was increased to 12 members to accommodate Mr. Hazen's appointment.